A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2030

Conditions

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

Interventions

DRUG

Atumelnant

Atumelnant, tablets, once daily by mouth, weight-based dosing

DRUG

Placebo

Placebo, tablets, once daily by mouth, weight-based dosing